 |
| Caption: This illustration depicts injectable nanoantennas being wirelessly activated by a magnetic field to generate localized electric fields that target a brain tumor. The magnified inset shows nanoparticles interacting with drug-resistant glioblastoma tissue. Image Credit: Baju Joy and Gopikrishna Pillai |
Scientific Frontline: Extended "At a Glance" Summary: Injectable Nanoantennas for Glioblastoma
The Core Concept: Researchers have developed injectable, wirelessly actuated nanoantennas—termed HITMAN (highly-localized electric-field-induced tumor therapy using magnetically actuated nanoantennas)—that generate localized electric fields to selectively destroy brain cancer cells without harming healthy tissue.
Key Distinction/Mechanism: When exposed to a low-frequency, non-heating magnetic field, the magnetostrictive components within the 150-nanometer antennas deform a piezoelectric film. This deformation produces localized electric fields that disrupt the inherent bioelectric currents of highly proliferative cancer cells, inducing protein unfolding, membrane damage, and endoplasmic reticulum stress, which ultimately leads to cell death.
Major Frameworks/Components:
- Piezoelectric Film Deformation: The mechanism relies on the conversion of magnetic energy into mechanical stress, which then generates an electric field via piezoelectricity.
- Cellular Disruption: The localized electric fields specifically target the bioelectric currents of cancer cells, exploiting their high protein-folding demand and abnormal membrane composition.
- Circulatronics Integration: A related technology developed in 2025 could allow these devices to be injected intravenously, utilizing living cells to cross the blood-brain barrier and evade the immune system.
Branch of Science: Bioengineering, Nanotechnology, Oncology, and Neuroscience.
Future Application: Beyond targeted glioblastoma treatment via direct injection or intravenous delivery (circulatronics), this technology holds potential for reducing tumor recurrence and metastasis, and could be adapted to treat other highly infiltrative or drug-resistant cancers.
Why It Matters: Glioblastoma is an extremely aggressive and treatment-resistant cancer with a median survival rate of 12 to 15 months; this minimally invasive technology eliminated 52.2 percent of drug-resistant cancer cells in lab tests (over five times more effective than standard chemotherapy) and extended median survival in animal models by over 50 percent with no detectable toxicity.
Magnetically Actuated Nanoantennas for Wireless Glioblastoma Therapy
To test HITMAN against the most clinically realistic version of this disease, the research team worked with tumor tissue obtained from patients diagnosed with aggressive and chemotherapy-resistant glioblastoma at Mayo Clinic. Using cells derived from this tissue in the laboratory, the researchers demonstrated that HITMAN eliminated 52.2 percent of these drug-resistant cancer cells—more than five times that achieved by the standard chemotherapy drug temozolomide (TMZ)—while leaving healthy neurons and brain-supporting astrocytes unharmed.
The team then implanted those patient-derived tumor cells into the brains of mice to recreate the disease in a living system. In these orthotopic animal models—widely regarded as the gold standard for preclinical brain tumor research—HITMAN substantially inhibited tumor growth, extending median survival by more than 50 percent with no detectable toxicity to major organs or surrounding healthy tissue.
The injectable nanoantennas can be activated wirelessly from outside the body by applying a low-frequency magnetic field (no higher than 200 kHz, to prevent tissue-damaging heat) that penetrates the skull and brain tissue. The magnetic field actuates magnetostrictive components within the nanoantennas, creating stress and strain. This mechanical response deforms a piezoelectric film, producing localized electric fields.
These localized electric fields preferentially attacked glioblastoma at the cellular level by disrupting the cells’ inherent bioelectric currents and fields, which regulate cellular function. This disruption provoked several antitumor mechanisms, including protein unfolding, membrane damage, and endoplasmic reticulum stress, curtailing the production of functional cellular proteins. These forms of cellular dysfunction ultimately led to cell death. The researchers noted that cancer cells were selectively targeted over healthy cells because of their high proliferative rate, which elevates the demand for protein folding, as well as their characteristic abnormalities in membrane composition and intracellular organelles.
In a wide array of control experiments, the researchers exposed glioblastoma cells to the nanoantennas without applying a magnetic field, and they also exposed the cancer cells to a magnetic field alone. These tests confirmed that the observed effects were indeed caused by the nanoantennas and their magnetic field activation. The team also tested for damaging side effects in the animal models’ major organs—the kidneys, liver, spleen, lungs, and heart—and detected none.
The research also demonstrated a significant reduction in the number of cancer cell colonies formed after the application of the nanoantennas, dropping from between 112 and 150 in the control groups to just 26 in the experimental group. This indicates a substantial potential to reduce tumor recurrence and metastasis.
If translated to clinical use, the nanoantennas, which are approximately 150 nanometers in size, could be injected through the skull. Sarkar points out, however, that a technology developed previously in her lab could make their deployment even simpler.
In 2025, Sarkar and her colleagues created “circulatronics,” a technology that could allow devices like the HITMAN nanoantennas to be administered through an injection in a patient’s arm and travel to a target region of the brain. In that previous work, the electronic devices were integrated with living cells so they would not be attacked by the body’s immune system and could easily cross the blood-brain barrier, as demonstrated in preclinical studies.
A glioblastoma diagnosis presents formidable treatment challenges. Because this type of cancer is extremely infiltrative, complete tumor removal is difficult to achieve and can affect cognitive function. Additionally, the tumors often resist radiotherapy and chemotherapy, and immunotherapy is hindered by an immunosuppressive tumor environment.
“The persistent failure of these therapies underscores the urgent need for novel approaches to target treatment-resistant glioblastoma cells,” the researchers write. “HITMAN offers a minimally invasive, spatially precise, and clinically translatable therapy for glioblastoma.”
Published in journal: Science Advances
Title: Magnetically actuated nanoantennas for wireless glioblastoma therapy
Authors: Monochura Saha, Ishaq N. Khan, Baju Joy, Shun-Ying Chen, Hao-Tung Yang, Preet Patel, Kyuho Jang, Pengrui Zhang, Faheem Azeemi, and Deblina Sarkar
Source/Credit: Massachusetts Institute of Technology | Michaela Jarvis / Media Lab
Edited by: Scientific Frontline
Reference Number: beng090926_01
